13F Data
13F filer · CIK 1300336

Tekla Capital Management LLC

Boston, MA · filing since Q2 2013 · last filing Aug 10, 2023
Reported value
$2.6B
$-71.2M vs prior
Positions
166
New / sold out
9 / 20
Added / reduced
28 / 31
Turnover
7.2%
buys $186.3M · sells $284.9M
Top-10 weight
40.3%

Biggest buys vs Q1 2023

ChangeSecurityShares changeChange %Est. trade value
AddedMerck & Co., Inc.+176,032+31.9%+$20.3M
AddedAmgen Inc.+60,600+10.9%+$13.5M
AddedRegeneron Pharmaceuticals, Inc.+18,365+12.8%+$13.2M
NewInsulet Corp.+43,847–+$12.6M
NewTenet Healthcare Corp.+149,070–+$12.1M
AddedBaxter International, Inc.+257,058+381.9%+$11.7M
AddedIQVIA Holdings Inc.+46,012+72.9%+$10.3M
AddedVaxcyte, Inc.+189,232+3784.6%+$9.5M
AddedDanaher Corp.+37,123+35.1%+$8.9M
NewHorizon Therapeutics plc+72,425–+$7.4M
27 more rows. Subscribe for $29/month to see every row, download the data and use the API.

Biggest sells vs Q1 2023

ChangeSecurityShares changeChange %Est. trade value
ReducedLLYEli Lilly and Company-75,565-26.2%$-35.4M
ReducedThe Cigna Group-86,292-47.2%$-24.2M
ReducedSeagen Inc.-112,332-50.0%$-21.6M
ReducedBristol-Myers Squibb Company-205,298-30.9%$-13.1M
ReducedUnitedhealth Group Inc.-27,212-11.6%$-13.1M
ReducedSarepta Therapeutics, Inc.-106,216-37.2%$-12.2M
ReducedIntuitive Surgical, Inc.-28,700-25.5%$-9.8M
Sold outTravere Therapeutics, Inc.-418,520-100.0%$-9.4M
Sold outLaboratory Corporation of America Holdings-40,042-100.0%$-9.2M
Reducedargenx SE-22,757-25.8%$-8.9M
41 more rows. Subscribe for $29/month to see every row, download the data and use the API.

Estimated trade value = change in shares × this quarter's implied price. 13F filings show quarter-end positions, not individual trades.

Reported value by quarter

Q2 2013: $735.4MQ3 2013: $898.8MQ4 2013: $952.5MQ1 2014: $1.0BQ2 2014: $1.1BQ3 2014: $2.1BQ4 2014: $2.1BQ1 2015: $2.5BQ2 2015: $2.8BQ3 2015: $2.8BQ4 2015: $2.8BQ1 2016: $2.4BQ2 2016: $2.4BQ3 2016: $2.6BQ4 2016: $2.3BQ1 2017: $2.6BQ2 2017: $2.7BQ3 2017: $2.8BQ4 2017: $2.6BQ1 2018: $2.6BQ2 2018: $2.6BQ3 2018: $2.8BQ4 2018: $2.3BQ1 2019: $2.5BQ2 2019: $2.5BQ3 2019: $2.3BQ4 2019: $2.6BQ1 2020: $2.2BQ2 2020: $2.6BQ3 2020: $2.7BQ4 2020: $2.8BQ1 2021: $2.9BQ2 2021: $3.1BQ3 2021: $3.1BQ4 2021: $3.1BQ1 2022: $2.8BQ2 2022: $2.5BQ3 2022: $2.4BQ4 2022: $2.6BQ1 2023: $2.6BQ2 2023: $2.6B
Q2 2013Q2 2023

Holdings · Q2 2023

#SecuritySharesValueWeight
1Amgen Inc.COMMON616,539$136.9M5.36%
2JNJJohnson & Johnson721,779$119.5M4.68%
3Gilead Sciences, Inc.COMMON1,533,884$118.2M4.63%
4Regeneron Pharmaceuticals, Inc.COMMON161,418$116.0M4.54%
5Vertex Pharmaceuticals Inc.COMMON318,043$111.9M4.38%
6LLYEli Lilly and Company213,352$100.1M3.92%
7Unitedhealth Group Inc.COMMON206,961$99.5M3.89%
8Merck & Co., Inc.COMMON728,154$84.0M3.29%
9AbbVie Inc.COMMON545,629$73.5M2.88%
10Biogen Inc.COMMON247,943$70.6M2.76%
156 more rows. Subscribe for $29/month to see every row, download the data and use the API.